"HIV-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
| Descriptor ID |
D015497
|
| MeSH Number(s) |
B04.820.650.589.650.350.400
|
| Concept/Terms |
HIV-1- HIV-1
- Human immunodeficiency virus 1
- HIV-I
- Immunodeficiency Virus Type 1, Human
- Human Immunodeficiency Virus Type 1
|
Below are MeSH descriptors whose meaning is more general than "HIV-1".
Below are MeSH descriptors whose meaning is more specific than "HIV-1".
This graph shows the total number of publications written about "HIV-1" by people in this website by year, and whether "HIV-1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 3 | 0 | 3 |
| 1998 | 2 | 1 | 3 |
| 1999 | 3 | 0 | 3 |
| 2000 | 2 | 1 | 3 |
| 2001 | 1 | 1 | 2 |
| 2002 | 5 | 1 | 6 |
| 2003 | 3 | 1 | 4 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 4 | 0 | 4 |
| 2007 | 4 | 1 | 5 |
| 2008 | 5 | 2 | 7 |
| 2009 | 5 | 2 | 7 |
| 2010 | 2 | 0 | 2 |
| 2011 | 5 | 2 | 7 |
| 2012 | 3 | 5 | 8 |
| 2013 | 4 | 0 | 4 |
| 2014 | 4 | 0 | 4 |
| 2015 | 3 | 1 | 4 |
| 2016 | 8 | 1 | 9 |
| 2017 | 7 | 4 | 11 |
| 2018 | 11 | 1 | 12 |
| 2019 | 6 | 2 | 8 |
| 2020 | 4 | 1 | 5 |
| 2021 | 4 | 1 | 5 |
| 2022 | 2 | 1 | 3 |
| 2023 | 5 | 0 | 5 |
| 2024 | 3 | 1 | 4 |
| 2025 | 0 | 3 | 3 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV-1" by people in Profiles.
-
DNA origami vaccines program antigen-focused germinal centers. Science. 2026 Feb 05; 391(6785):eadx6291.
-
Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic. J Antimicrob Chemother. 2025 11 04; 80(11):3092-3100.
-
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process. Lancet HIV. 2025 Sep; 12(9):e649-e659.
-
HIV Viral Rebound on Dolutegravir, Lopinavir, and Efavirenz: National Program Data Analysis From Ukraine. J Acquir Immune Defic Syndr. 2025 Aug 01; 99(4):395-404.
-
Mutability and hypermutation antagonize immunoglobulin codon optimality. Mol Cell. 2025 Jan 16; 85(2):430-444.e6.
-
Polyfunctionality and breadth of HIV-1 antibodies are associated with delayed disease progression. PLoS Pathog. 2024 12; 20(12):e1012739.
-
A multiplexed real-time PCR assay for simultaneous quantification of human immunodeficiency virus and Hepatitis B virus for low-and-middle- income countries. J Virol Methods. 2024 12; 330:115026.
-
HIV-1 Vpr combats the PU.1-driven antiviral response in primary human macrophages. Nat Commun. 2024 06 29; 15(1):5514.
-
Antiviral HIV-1 SERINC restriction factors disrupt virus membrane asymmetry. Nat Commun. 2023 07 20; 14(1):4368.
-
Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis. AIDS. 2023 09 01; 37(11):1711-1714.